ClinicalTrials.gov
public full text
Public Domain
Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study
At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy. Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Patients on Antithrombotics for Colonoscopy#832171
- Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients#886394
- Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule#1171086
- Fundic Gland Polyps and Proton Pump Inhibitor (PPI) Drugs#889675
- Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus#1164604
Record · ID 1162894
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive